GSA Capital Partners LLP Buys New Shares in Zentalis Pharmaceuticals, Inc. $ZNTL

Key Points

• GSA Capital Partners acquired 374,260 Zentalis Pharmaceuticals shares in the second quarter, worth approximately $1.815 million and representing a 0.53% stake.
• Analyst sentiment is mixed, with four Buy, four Hold, and one Sell rating; the consensus is Hold with an average price target of $6.75.
• Zentalis reported a quarterly loss of $0.59 per share, missing the $0.49 consensus estimate. The stock opened at $3.56, versus a one-year range of $1.21 to $6.95.

GSA Capital Partners LLP bought a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 374,260 shares of the company's stock, valued at approximately $1,815,000. GSA Capital Partners LLP owned 0.53% of Zentalis Pharmaceuticals as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of the business. Marquette Asset Management LLC bought a new stake in Zentalis Pharmaceuticals during the second quarter valued at about $141,000. Seven Fleet Capital Management LP bought a new position in shares of Zentalis Pharmaceuticals in the first quarter worth about $257,000. CTC Alternative Strategies Ltd. purchased a new stake in shares of Zentalis Pharmaceuticals during the first quarter worth about $29,000. ADAR1 Capital Management LLC grew its position in shares of Zentalis Pharmaceuticals by 80.8% during the first quarter. ADAR1 Capital Management LLC now owns 144,636 shares of the company's stock worth $338,000 after purchasing an additional 64,636 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp bought a new stake in Zentalis Pharmaceuticals during the 1st quarter valued at approximately $112,000.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Mizuho started coverage on Zentalis Pharmaceuticals in a report on Friday, July 17th. They issued an "outperform" rating and a $8.00 price target on the stock. Rodman & Renshaw started coverage on shares of Zentalis Pharmaceuticals in a research report on Thursday, July 23rd. They set a "buy" rating and a $11.00 price objective on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 8th. Finally, HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Four research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals has an average rating of "Hold" and an average target price of $6.75.

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL opened at $3.56 on Monday. The firm has a market capitalization of $255.15 million, a price-to-earnings ratio of -1.83 and a beta of 1.92. The business has a 50 day simple moving average of $4.34 and a 200-day simple moving average of $3.64. Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.21 and a 1 year high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.10). As a group, analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.14 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis' research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company's lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.

Want to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source